Unlike insulin and sulfonylureas, GLP-1 receptor agonists stimulate insulin release only when blood glucose is elevated, a mechanism associated with reduced hypoglycemia risk in the general diabetic population
It supports fat transport into mitochondria and can deliver small, measurable improvements in body weight and fat mass for some people, especially those with overweight or obesity, but it is not a substitute for comprehensive diet, activity, or medically supervised therapies
For instance, combining GLP-1 therapy with proper sleep hygiene can enhance outcomes
How much do tirzepatide and semaglutide cost in 2026
#Pharmacology #ClinicalPharmacy #DrugMetabolism #Healthcare #MedicalEducation To view or add a comment, sign in The obesity drug space is moving faster than any other therapeutic category right now